CorMedix (CRMD) Misses Q4 EPS by 69c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.16, $0.69 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.48 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• argenx SE (ARGX) PT Raised to $1,200 at Citizens on VYVGART Indication Expansion
• XP Inc eyes US banking license as next business step